AGAIN, hope this company has enough common sense to understand that, But I doubt they have any common sense at all when it comes to this stock. Dumb #$%$,es when it comes to shareholders
METHODS AND RESULTS:
A total of 706 patients with SCAD and a history of acute coronary syndrome (ACS) were analyzed over a follow up period of 2.2 years. The primary endpoint was the occurrence of an ischemic event (any SCA, stroke or transient ischemic attack), heart failure, or death. A clinical risk scale derived from the LIPID study significantly predicted the development of the primary endpoint, with an area under the ROC curve (Receiver Operating Characteristic) A composite score was developed by adding the scores of the LIPID and scale decile levels of MCP -1, galectin -3 and NT-proBNP. The predictive value improved with an area under the curve . A score greater than 21.5 had a sensitivity of 74% and a specificity of 61% for the development of the primary endpoint
Plasma levels of MCP-1, galectin -3 and NT-proBNP improve the ability of the LIPID clinical scale to predict the prognosis of patients with SCAD.
DEQI enters mobile poker arena by purchasing the game Actua Poker and will begin distribution of the game to all markets. Management looks top capitalize on exploding demand for mobile gaming apps in the poker niche
pump and dump scam only 5k in revs...lol
DEQI sets sights on breakout trading as management unveils three new titles to the company’s line-up. Is $2.50 a realistic trading price for the stock?
At present, there is no tool validated by scientific societies for risk stratification of patients with stable coronary artery disease (SCAD). It has been shown that plasma levels of monocyte chemoattractant protein-1 (MCP-1), galectin-3 and pro-B-type natriuretic peptide amino-terminal (NT-proBNP) have prognostic value in this population.
To analyze the prognostic value of a clinical risk scale published in Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) study and determining its predictive capacity when combined with plasma levels of MCP-1, galectin-3 and NT-proBNP in patients with SCAD.
Can George Metos, former owner and founder of Sculptured Software, Inc. bring DEQI into the big leagues? Former developer of big gaming titles like Mortal Kombat brings extensive gaming development experience to DEQI
We should contact management and let them know that they should put out press releases when these studies come out. Even if they regroup two or more studies and issue one press release informing us of one or more studies done. This is important progress which should not be underestimated. It will also give more confidence to present and future shareholders.
Sentiment: Strong Buy
Usefulness of Combining Galectin-3 and BIVA Assessments in Predicting Short- and Long-Term Events in Patients Admitted for Acute Heart Failure
Conclusion - In patients admitted for AHF an early assessment of GAL3 and BIVA seems to be useful in identifying patients at high risk for death and rehospitalization at short and long term. Combining the biomarker and the device could be of great utility since they are monitoring the severity of two pathophysiological different mechanisms underlining the severity of disease: heart fibrosis and fluid overload. GAL3 per se has the strongest independent predicting value for death and rehospitalization at 30 days with a cut-off of 32.24 ng/mL. The use of combining GAL3 and BIVA assessment, at the moment of AHF patients' presentation, could support decision making and different therapeutic approach.
June 23, 2014 — BG Medicine Inc. earlier this year announced the issuance of patent 8,672,857, titled “Galectin-3 and Cardiac Resynchronization Therapy,” by the United State Patent and Trademark Office. The patent claims methods for predicting responsiveness to cardiac resynchronization therapy by the measurement of the concentration of the protein galectin-3 in blood.
Cardiac resynchronization therapy, also referred to as biventricular pacing, involves the implantation of a specialized pacemaker device to attempt to improve the heart's rhythm and alleviate symptoms associated with arrhythmia in heart failure.
"The issuance of this patent both strengthens and broadens BG Medicine's patent portfolio covering galectin-3 testing," said Paul R. Sohmer, M.D., president and CEO of BG Medicine. "We will continue to aggressively pursue the protection of our intellectual property related to galectin-3."
Had they issued a press release we would have gone up 30-50 cents, just being associated with Boston Scientific. Mind boggling how conservative they are.
Sentiment: Strong Buy
Mind boggling why the company would not issue a press release for this. This is just one of these other clinical studies which has been performed in preparation for FDA clearance and Abbotts launch of automated Galectin3 testing. These studies will establish the proper protocol to follow when deciding on testing for Gal3. The knowlege gained will help establish the guidelines for deciding on when a test is necessary, how to interpret the results and what follow up treatment is needed based on Gal 3 levels. All in preparation for commercial launch of the automated testing and marketing of the test. These guidelines being established will make it easy for Heart specialists to make proper use of Gal3 testing and thus easy for them to incorporate the test in their routine standard of care practice . There is no way the FDA can refuse clearance of such a valuable test. IMHO
Sentiment: Strong Buy
I cant for the life of me understand why BG Medicine does not think this news is worthy of a Press Release, This is the frustration most of us feel with this company,
Guys...the Abbott automated G3 test WILL get FDA cleared via 510(k). They have demonstrated good concordance with BGMDs ELISA-based test, so this should be an easy lay-up for Abbott. If BGMDs test was not already FDA cleared, then I would say it's a #$%$ shoot, but BGMD already has 510(k) FDA approval for their non-automated version of G3, so the bar for Abbott (IMHO) is much easier to meet because all they really need to show is that their automated platform is reproducible and had good concordance with BGMDs ELISA-based test.
Conclusions - Elevated galectin-3 was found to be an independent predictor of adverse
HF outcome in patients with mildly symptomatic HF. A significant interaction of device
randomization group with pre-implantation galectin-3 level was detected, with HF
patients having the highest baseline galectin-3 levels deriving a disproportionately larger
benefit from CRT-D therapy. = Cardiac Resynchronization Therapy
Boston Scientific Makes Defibrillator.s , BG Medicine Has A Patent For Cardiac Resynchronization Therapy, OH BOY THIS COULD GET INTERESTING
Plasma Galectin-3 and Heart Failure Outcomes in MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial––Cardiac Resynchronization Therapy)
Craig M. Stolen, PhD Aram Adourian, PhD Timothy E. Meyer, PhD Kenneth M. Stein, MD Scott D. Solomon, MD
PII: S1071-9164(14)00695-2 DOI: 10.1016/j.cardfail.2014.07.018 Reference: YJCAF 3369
To appear in: Journal of Cardiac Failure
Received Date: 7 November 2013 Revised Date: 25 July 2014 Accepted Date: 29 July 2014
Plasma Galectin-3 and Heart Failure Outcomes in MADIT-CRT
(Multicenter Automatic Defibrillator Implantation Trial--Cardiac
Craig M. Stolen, PhD1, Aram Adourian, PhD2, Timothy E. Meyer, PhD1, Kenneth
M. Stein, MD1, and Scott D. Solomon, MD3
1 Boston Scientific Corporation, St Paul, MN;
2 BG Medicine, Inc. Waltham, MA;
3 Department of Medicine, Brigham and Women’s Hospital, Boston, MA
Short Title: Galectin-3 in MADIT-CRT
Funding: This work was supported by Boston Scientific Corporation and BG Medicine,
Correspondence: Craig M. Stolen, Boston Scientific Corporation